Is Now The Perfect Time To Buy AstraZeneca plc, Greggs plc And Stanley Gibbons Group PLC?

Are these 3 stocks ripe for investment? AstraZeneca plc (LON: AZN), Greggs plc (LON: GRG) and Stanley Gibbons Group PLC (LON: SGI)

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Turning companies around from disappointing financial performance to superb profitability is never an easy task. After all, there is usually a very good reason for their bottom lines falling, whether that is a change in customer tastes, a recession or poor decisions by management which have caused the business to become uncompetitive. And, even if the right strategy is put in place, it usually takes a considerable amount of time for even the best of companies to mount a successful comeback.

One stock which is very much on the up is AstraZeneca (LSE: AZN). It has endured a very challenging period of time with a number of key, blockbuster drugs coming off patent and being exposed to generic competition. However, it was a poor response by the business which led to its downfall, since it lacked a strong pipeline of new drugs to take the places of the ones which lost patent protection. Furthermore, policies such as a major share buyback were using up vital cash resources which could have been better spent on improving the company’s long term outlook.

However, under a different management team, AstraZeneca has got its house in order. It has embarked on a highly successful acquisition spree, with its sound balance sheet and excellent cash flow being used to bring on board a number of new drugs and potential treatments which, in years to come, could become blockbuster drugs for the business. And, while the company’s share price has soared by 46% since the start of 2013 (while also paying a yield of 6.1% throughout the period), its shares trade on a relatively appealing price to earnings (P/E) ratio of 15.4.

Also making a successful turnaround is high-street food business Greggs (LSE: GRG). It lost its way under previous management, with the business attempting to diversify its offering through more upmarket coffee shops and a range of chilled/frozen foods on sale in supermarkets. In other words, it appeared to lose focus on its core offering but, under a different management team, Greggs has become a more efficient and simple business. For example, it has closed unprofitable stores, improved its supply chain and focused on giving customers what they want: good value food in convenient locations.

Furthermore, today’s update from Greggs is very positive. It has reported strong sales in a low inflation environment and expects its full-year results to be ahead of market expectations. As such, its shares are up by 6% today, making it a gain of 56% since the turn of the year.

However, Greggs is likely to see margins squeezed in future years from the impact of the new living wage. And, while it already pays its staff a higher rate than the minimum wage, for a business which is focused on value it may be unable to pass all of the additional costs on to consumers.

Meanwhile, collectibles company Stanley Gibbons (LSE: SGI) appears to be in need of a turnaround, with its shares slumping by 27% today after a profit warning. It continues to struggle with a slowing Asian economy and, while it states in today’s update that its second half performance will be much better than its first, margins are coming under increasing pressure.

As a result, its short term performance is likely to be rather disappointing and its shares may continue the run which has seen them fall by 62% since the turn of the year. However, Stanley Gibbons remains a financially sound, niche business which has long term potential to recover as the world economy stabilises. And, with it having a price to book value (P/B) ratio of just 0.8, it appears to be worth buying for the long term.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Peter Stephens owns shares of AstraZeneca. The Motley Fool UK has no position in any of the shares mentioned. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Will the beaten-down BT share price go lower from here?

The BT share price is largely unmoved over the past month and it's trading towards the bottom of its range.…

Read more »

A young black man makes the symbol of a peace sign with two fingers
Investing Articles

2 magnificent FTSE 250 value stocks to consider today

The FTSE 250 is home to scores of brilliant value stocks right now. Here our writer Royston Wild picks out…

Read more »

Young woman holding up three fingers
Investing Articles

My 2 favourite FTSE 100 shares for May!

After a great April, the FTSE 100 index is up 6.2% in 2024. And though these two Footsie stocks have…

Read more »

Silhouette of a bull standing on top of a landscape with the sun setting behind it
Investing Articles

2 UK blue-chip shares that could soar as the FTSE 100 bull run begins

The FTSE 100's reaching record high after record high. And Royston Wild thinks these brilliant blue-chips could continue climbing.

Read more »

Number three written on white chat bubble on blue background
Investing Articles

Just released: the 3 best growth-focused stocks to consider buying in May [PREMIUM PICKS]

Our goal here is to highlight some of our past recommendations that we think are of particular interest today, due…

Read more »

Portrait of elderly man wearing white denim shirt and glasses looking up with hand on chin. Thoughtful senior entrepreneur, studio shot against grey background.
Investing Articles

With £1,000 to invest, should I buy growth stocks or income shares?

Dividend shares are a great source of passive income, but how close to retirement, should investors think about shifting away…

Read more »

Warren Buffett at a Berkshire Hathaway AGM
Investing Articles

Warren Buffett should buy this flagging FTSE 100 firm!

After giving $50bn to charity, Warren Buffett still has a $132bn fortune. Also, his company has $168bn to spend, so…

Read more »

Middle-aged white man wearing glasses, staring into space over the top of his laptop in a coffee shop
Investing For Beginners

I wish I’d known about this lucrative style of stock market investing 20 years ago

Research has shown that over the long term, this style of investing can generate returns in excess of those provided…

Read more »